Compare iShares MSCI South Korea ETF (EWY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Sanofi SA — how do they compare? iShares MSCI South Korea ETF trades at $175.12, while Sanofi SA trades at $43.56 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while iShares MSCI South Korea ETF pays none, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| EWY | SNY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $52.34 |
52-Week Low | $71.22 | $41.33 |
Market Cap | — | $104.30B |
Enterprise Value | — | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, trades at $174.49, up 6.97% in 24 hours, with a neutral technical signal overall. Recent news highlights South Korea's semiconductor sector volatility and government support initiatives, including a $3.52 billion fund for chip materials. The ETF's performance is tied to heavyweights like Samsung and SK Hynix, which have faced sharp declines amid AI-driven market swings.
Outlook remains cautious due to sector concentration risks and foreign capital outflows, but long-term potential exists if semiconductor demand stabilizes. Investors face volatility from leveraged ETF speculation curbs and global tech sentiment shifts, requiring careful risk assessment amid mixed analyst views.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
